Experiences Associated with the Use of Live Poliovirus Vaccine in Hungary, 1959–1982

Domok, I

doi:10.1093/clinids/6.supplement_2.s413

Cited by 29 publications

(18 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was shown in Singapore that massive administration of MOPV type 2 could significantly interfere with promulgation of an outbreak of poliomyelitis caused by a wild poliovirus type 1 [43]. In contrast, seroconversion after mass campaigns in Hungary was similar whether they were conducted in the winter or the fall, when enterovirus excretion rates were higher [44]. It is likely that the interference at least partially explains the decreased seroconversion rates to MOPV in countries where hot climates and poor sanitation are conducive to enterovirus circulation [45].…”

Section: Immunogenicitymentioning

confidence: 99%

See 1 more Smart Citation

Sabin Monovalent Oral Polio Vaccines: Review of Past Experiences and Their Potential Use after Polio Eradication

2001

View full text Add to dashboard Cite

After global eradication of polio is achieved, there will be a need for stockpiles of vaccine to combat potential outbreaks of poliomyelitis caused by (1) unforeseen release of polioviruses, (2) continued circulation of vaccine-derived strains, or (3) prolonged replication of polioviruses in immunodeficient persons. We conducted a review of the literature to document the immunogenicity and safety of monovalent Sabin vaccines, considered ideal candidates for these situations. The National Library of Medicine archives were searched for the keywords "polio," "monovalent," and "vaccine." Seroconversion rates for monovalent Sabin type 1 ranged from 53% to 100% (median, 95%); for type 2, 77%-100% (median, 93%); and for type 3, 52%-100% (median, 85%). The risk of vaccine-associated poliomyelitis per million persons vaccinated ranged from.05 to 0.99 (type 1), 0-0.65 (type 2), and 1.18-8.91 (type 3). Single-dose monovalent Sabin vaccines are highly immunogenic and safe and should be considered for stockpiles of vaccine to provide an effective response to potential outbreaks of poliomyelitis in the post-eradication period.

show abstract

Section: Immunogenicitymentioning

confidence: 99%

“…Dömök described the experience in Hungary, where for 120 years MOPV had been delivered through biannual mass campaigns to children between 2 and 38 months of age [44]. These campaigns effectively eliminated indigenous transmission of wild poliovirus.…”

Section: Safetymentioning

confidence: 99%

Sabin Monovalent Oral Polio Vaccines: Review of Past Experiences and Their Potential Use after Polio Eradication

2001

View full text Add to dashboard Cite

show abstract

“…In Hungary, a country with a significant problem with VAPP cases [34] a sequential schedule comprising one dose of IPV followed by OPV led to a complete disappearance of VAPP [35,36]. Another study in Hungary found that one or three doses of IPV followed by three doses of OPV resulted in individual protection against paralytic poliomyelitis as well as reduced cases of VAPP in the population [36,37]. Additional experiences in India and the USA have shown that receiving IPV before OPV appears to protect against VAPP [7,34,38].…”

Section: • • Ipv Before Opvmentioning

confidence: 99%

Polio Vaccination: Past, Present and Future

et al. 2015

View full text Add to dashboard Cite

Live attenuated oral polio vaccine (OPV) and inactivated polio vaccine (IPV) are the tools being used to achieve eradication of wild polio virus. Because OPV can rarely cause paralysis and generate revertant polio strains, IPV will have to replace OPV after eradication of wild polio virus is certified to sustain eradication of all polioviruses. However, uncertainties remain related to IPV's ability to induce intestinal immunity in populations where fecal-oral transmission is predominant. Although substantial effectiveness and safety data exist on the use and delivery of OPV and IPV, several new research initiatives are currently underway to fill specific knowledge gaps to inform future vaccination policies that would assure polio is eradicated and eradication is maintained.

show abstract

“…When one or two IPV doses are given prior to OPV, the existing immunity will reduce the risk of cVDPV/VAPP. Effectiveness of sequential schedules has been clinically proven by many studies 16,17,18 .…”

Section: Analysis Of the Current Scenariomentioning

confidence: 99%

Moving from oral poliovirus vaccine to inactivated poliovirus vaccine in Sri Lanka: The rationale and challenges

Perera

2017

Sri Lanka J Child Health

View full text Add to dashboard Cite

Experiences Associated with the Use of Live Poliovirus Vaccine in Hungary, 1959–1982

Cited by 29 publications

References 1 publication

Sabin Monovalent Oral Polio Vaccines: Review of Past Experiences and Their Potential Use after Polio Eradication

Sabin Monovalent Oral Polio Vaccines: Review of Past Experiences and Their Potential Use after Polio Eradication

Polio Vaccination: Past, Present and Future

Moving from oral poliovirus vaccine to inactivated poliovirus vaccine in Sri Lanka: The rationale and challenges

Contact Info

Product

Resources

About